These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 36293127)
1. Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy Resistance. Rudich A; Garzon R; Dorrance A Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293127 [TBL] [Abstract][Full Text] [Related]
2. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1. Lu YH; Huang ZY Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898 [TBL] [Abstract][Full Text] [Related]
6. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Kaehler M; Cascorbi I Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601 [TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824 [TBL] [Abstract][Full Text] [Related]
9. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia. Wu A; Liu X; Fruhstorfer C; Jiang X Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279 [TBL] [Abstract][Full Text] [Related]
10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
11. miRNAs in chronic myeloid leukemia: small molecules, essential function. Litwińska Z; Machaliński B Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267 [TBL] [Abstract][Full Text] [Related]
13. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia. Huang R; Kang Q; Liu H; Li Y Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311 [TBL] [Abstract][Full Text] [Related]
14. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia]. Tsubaki M Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658 [TBL] [Abstract][Full Text] [Related]
15. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1 Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618 [TBL] [Abstract][Full Text] [Related]
16. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
17. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872 [TBL] [Abstract][Full Text] [Related]
18. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078 [TBL] [Abstract][Full Text] [Related]
19. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880 [TBL] [Abstract][Full Text] [Related]
20. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. Al Hamad M F1000Res; 2021; 10():1288. PubMed ID: 35284066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]